News

Enspryng (satralizumab) is superior to conventional immunosuppressive therapies in reducing the risk of relapses in people with neuromyelitis optica spectrum disorder (NMOSD) for up to three years, and with a comparable safety profile, according to a real-world study. Similar results were obtained when analyzing data only from NMOSD…

Newer, more potent therapies offer greater benefit than standard immunosuppressants in reducing relapse rates for people who develop neuromyelitis optica spectrum disorder (NMOSD) after the age of 50, according to a large, single-center study in China. While people with late-onset NMOSD experienced more severe symptoms at onset and during…

People with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of chitotriosidase-1 (CHIT1), a protein involved in immune and inflammatory responses, in their cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord, a study shows. CSF CHIT1 levels were also significantly associated with NMOSD activity and severity.

Double-filtration plasmapheresis (DFPP), an advanced blood-cleaning procedure, is equally effective as high-dose corticosteroids for treating acute attacks associated with neuromyelitis optica spectrum disorder (NMOSD), but comes with fewer side effects, according to a new study from China. DFPP selectively removes disease-driving self-reactive antibodies from the bloodstream while retaining…

Different patterns of shrinkage in the brain and spinal cord are associated with distinct clinical outcomes in people with neuromyelitis optica spectrum disorder (NMOSD), a study reports. Findings suggest that NMOSD patients showing shrinkage, or atrophy, in outer brain regions are more likely to experience substantial physical disability and/or…

Low vitamin D levels, certain infections, and specific dietary habits may increase the risk of developing neuromyelitis optica spectrum disorder (NMOSD). That’s according to the findings of a systematic review that analyzed data from 50 studies involving more than 21,000 people worldwide. Certain modifiable factors, such as diets high…

People with neuromyelitis optica spectrum disorder (NMOSD) have abnormally high levels of S100A9, a protein that drives the inflammatory activity of certain immune cells, a study discovered. According to the researchers, higher S100A9 levels in the blood were significantly associated with more severe disability among patients. These findings thus…

Ofatumumab, a medication approved for multiple sclerosis (MS), may effectively prevent relapses and disability in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study in China. At their last follow-up, about 80% of the 112 patients analyzed were free from relapses, and more than 60% experienced significant reductions…

People testing negative for self-reactive antibodies against aquaporin-4 (AQP4-IgGs) — the type of antibody most commonly linked to neuromyelitis optica spectrum disorder (NMOSD) — rarely become positive for these antibodies on subsequent tests. These are the findings of a real-world study in the U.S. involving 451 people suspected of…

Higher blood levels of the glial fibrillary acidic protein (GFAP) are significantly associated with shrinkage in certain brain regions of people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against the AQP4 protein, a study showed. This association was not observed in people with myelin oligodendrocyte glycoprotein antibody-associated…